These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 21330830)

  • 1. Phase II clinical study of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 101 Group Study).
    Shoji T; Takatori E; Omi H; Kumagai S; Yoshizaki A; Yokoyama Y; Mizunuma H; Fujimoto T; Takano T; Yaegashi N; Tase T; Nakahara K; Kurachi H; Nishiyama H; Sugiyama T
    Int J Gynecol Cancer; 2011 Jan; 21(1):44-50. PubMed ID: 21330830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of oral etoposide plus intravenous irinotecan in patients with platinum-resistant and taxane-pretreated ovarian cancer (JCOG0503).
    Matsumoto K; Katsumata N; Shibata T; Satoh T; Saitou M; Yunokawa M; Takano T; Nakamura K; Kamura T; Konishi I
    Gynecol Oncol; 2015 Feb; 136(2):218-23. PubMed ID: 25449313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot study evaluating the efficacy and toxicity of irinotecan plus oral etoposide for platinum- and taxane-resistant epithelial ovarian cancer.
    Nishio S; Sugiyama T; Shouji T; Yoshizaki A; Kitagawa R; Ushijima K; Kamura T
    Gynecol Oncol; 2007 Aug; 106(2):342-7. PubMed ID: 17499346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study).
    Shoji T; Takatori E; Omi H; Kagabu M; Honda T; Futagami M; Yokoyama Y; Kaiho M; Tokunaga H; Otsuki T; Takano T; Yaegashi N; Kojimahara T; Ohta T; Nagase S; Soeda S; Watanebe T; Nishiyama H; Sugiyama T
    Cancer Chemother Pharmacol; 2017 Aug; 80(2):355-361. PubMed ID: 28656383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of oral etoposide and intravenous irinotecan for patients with platinum-resistant and taxane-pretreated ovarian cancer: Japan Clinical Oncology Group Study 0503.
    Matsumoto K; Katsumata N; Saito I; Shibata T; Konishi I; Fukuda H; Kamura T
    Jpn J Clin Oncol; 2012 Mar; 42(3):222-5. PubMed ID: 22323553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane. Results from a multicenter phase I/II study.
    Gronlund B; Engelholm SA; Horvath G; Mäenpää J; Ridderheim M
    Cancer; 2005 Apr; 103(7):1388-96. PubMed ID: 15719439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
    Verschraegen CF; Kudelka AP; Hu W; Vincent M; Kavanagh JJ; Loyer E; Bastien L; Duggal A; De Jager R
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):1-7. PubMed ID: 14586557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6).
    Yoshino K; Kamiura S; Yokoi T; Nakae R; Fujita M; Takemura M; Adachi K; Wakimoto A; Nishizaki T; Shiki Y; Tsutsui T; Kanda Y; Kobayashi E; Hashimoto K; Mabuchi S; Ueda Y; Sawada K; Tomimatsu T; Kimura T
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1239-1247. PubMed ID: 29080971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of irinotecan plus doxorubicin for early recurrent or platinum-refractory ovarian cancer: interim analysis.
    Nishimura S; Tsuda H; Hashiguchi Y; Kokawa K; Nishimura R; Ishiko O; Kamiura S; Hasegawa K; Umesaki N
    Int J Gynecol Cancer; 2007; 17(1):159-63. PubMed ID: 17291248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.
    Ushijima K; Kamura T; Tamura K; Kuzuya K; Sugiyama T; Noda K; Ochiai K
    Int J Clin Oncol; 2013 Feb; 18(1):126-31. PubMed ID: 22127346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
    Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
    Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study).
    Shoji T; Takatori E; Kaido Y; Omi H; Yokoyama Y; Mizunuma H; Kaiho M; Otsuki T; Takano T; Yaegashi N; Nishiyama H; Fujimori K; Sugiyama T
    Cancer Chemother Pharmacol; 2014 May; 73(5):895-901. PubMed ID: 24585045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of carboplatin and weekly irinotecan combination chemotherapy in recurrent ovarian cancer: a Kansai clinical oncology group study (KCOG0330).
    Tsubamoto H; Kawaguchi R; Ito K; Shiozaki T; Takeuchi S; Itani Y; Arakawa A; Tabata T; Toyoda S
    Anticancer Res; 2013 Mar; 33(3):1073-9. PubMed ID: 23482784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer.
    Polyzos A; Kosmas C; Toufexi H; Malamos N; Lagadas A; Kosmidis C; Ginopoulos P; Ziras N; Kandilis K; Georgoulias V
    Anticancer Res; 2005; 25(5):3559-64. PubMed ID: 16101180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysis.
    Sakamoto T; Yasui H; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamazaki K; Taku K; Machida N; Todaka A; Tomita H; Tsushima T; Taniguchi H; Hamauchi S
    Int J Clin Oncol; 2010 Jun; 15(3):287-93. PubMed ID: 20217447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study.
    Lan CY; Wang Y; Xiong Y; Li JD; Shen JX; Li YF; Zheng M; Zhang YN; Feng YL; Liu Q; Huang HQ; Huang X
    Lancet Oncol; 2018 Sep; 19(9):1239-1246. PubMed ID: 30082170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
    Kim BG; Oh SY; Kwon HC; Lee S; Lee DM; Kim SG; Kim DK; Jang JS; Kim MC; Kim SH; Kim HJ
    Am J Clin Oncol; 2010 Jun; 33(3):246-50. PubMed ID: 19770628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical trial of alternating belotecan and oral etoposide in patients with platinum-resistant or heavily treated ovarian cancer.
    Hwang JH; Yoo HJ; Lim MC; Seo SS; Park SY; Kang S
    Anticancer Drugs; 2012 Mar; 23(3):321-5. PubMed ID: 22156765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer.
    Caponigro F; Willemse P; Sorio R; Floquet A; van Belle S; Demol J; Tambaro R; Comandini A; Capriati A; Adank S; Wanders J
    Invest New Drugs; 2005 Jan; 23(1):85-9. PubMed ID: 15528985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.